IP Library Patent Application 11516212
Patent Application
App. No. 11/516,212

Diagnostic markers of wound infection III

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
11/516,212
Abstract

The present invention relates to a method of diagnosis or prognosis of a mammalian wound infection, said method comprising the step of measuring the level of at least one cell surface receptor in a sample of wound fluid. The preferred cell surface receptors are Intercellular adhesion molecule-1 (ICAM 1) and Tumor Necrosis Factor Receptor-2 (TNF-RII). The present invention also provides devices (e.g. biosensors) for use in such methods, and methods and products for diagnosing and treating infected wounds.

Claims (11)

1 . A method of diagnosis or prognosis of a mammalian wound infection, said method comprising the step of measuring the level of at least one cell surface receptor in a sample of wound fluid.

2 . A method according to claim 1 wherein the cell surface receptor is selected from the group consisting of ICAM 1, TNF-RII, and combinations thereof.

3 . A method according to claim 2 wherein the method is an in vitro method carried out on a sample of wound fluid that has been removed from a patient.

4 . A method according to claim 2 , wherein said step of measuring comprises contacting the sample of wound fluid with an immunological binding partner for a cell surface receptor.

5 . A method according to claim 4 , further comprising comparing the measured level of said one or more cell surface receptors in said sample of wound fluid with a reference level characteristic of a non-infected wound.

6 . A method according to claim 5 , wherein the method comprises sampling the wound fluid at intervals of from about 1 hour to about 24 hours and measuring the level of said one or more cell surface receptors in the samples obtained at said intervals.

7 . A method according to claim 5 , wherein the method further comprises measuring a total protein content of the wound fluid and normalising the measured levels of said one or more cell surface receptors to constant total protein content.

8 . A method for the treatment of a mammalian wound comprising the steps of measuring the level of one or more cell surface receptors selected from the group consisting of ICAM 1, TNF-RII in a sample of wound fluid, and applying an antimicrobial wound dressing to the wound selectively if the presence or level of said marker is indicative of wound infection wherein the step of measuring the level of one or more cell surface receptors comprises contacting the sample of wound fluid with an immunological binding partner for a cell surface receptor comparing the measured level of said one or more cell surface receptors in said sample of wound fluid with a reference level characteristic of a non-infected wound.

9 . A method according to claim 8 , further comprising applying a wound dressing that is substantially free of antimicrobial agents to the wound if the said presence or level is indicative of absence of wound infection.

10 . A method according to claim 8 , wherein the method comprises sampling the wound fluid at intervals, for example at intervals of from 1 hour to 24 hours, and selecting an antimicrobial or non-antimicrobial dressing to treat the wound at said intervals in response to the measured presence or level of said marker.

11 . A method according to claim 10 , wherein the antimicrobial wound dressing is applied to the wound if said level is increasing over time, and the non-antimicrobial dressing is applied to the wound if said level is decreasing over time.

Assignments (6)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 5, 2014
From: SYSTAGENIX WOUND MANAGEMENT (US), INC.
To: WOUNDCHECK LABORATORIES (US), INC.
Reel/Frame 033682/0309 →
RELEASE OF SECURITY INTEREST Recorded Oct 28, 2013
From: J.P. MORGAN EUROPE LIMITED
To: SYSTAGENIX WOUND MANAGEMENT (US), INC.
Reel/Frame 031506/0186 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 21, 2010
From: ETHICON, INC.; JOHNSON & JOHNSON MEDICAL LIMITED
To: SYSTAGENIX WOUND MANAGEMENT IP CO. B.V.
Reel/Frame 024563/0344 →
SECURITY AGREEMENT Recorded Jan 30, 2009
From: SYSTAGENIX WOUND MANAGEMENT (US), INC.
To: J.P. MORGAN EUROPE LIMITED
Reel/Frame 022177/0037 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 8, 2009
From: ETHICON, INC.; JOHNSON & JOHNSON MEDICAL LIMITED
To: SYSTAGENIX WOUND MANAGEMENT (US), INC.
Reel/Frame 022071/0762 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 6, 2006
From: CLARK, RACHAEL L.; CULLEN, BREDA M.
To: ETHICON, INC.
Reel/Frame 018280/0638 →